Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 9/20 | 0.71 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.53 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12813071 | 0.98 | ROCK1 (0.69) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| SCHEMBL6761496 | 0.91 | ROCK1 (0.72) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| SCHEMBL9377412 | 0.83 | ROCK1 (1.00) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL12813181 | 0.82 | ROCK1 (0.97) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| SCHEMBL1612239 | 0.80 | MAP3K14 (0.74) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| SCHEMBL5090531 | 0.78 | ROCK1 (0.66) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| SCHEMBL12813011 | 0.76 | ROCK1 (0.63) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| SCHEMBL15831287 | 0.76 | ROCK1 (0.55) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| SCHEMBL29721478 | 0.76 | ROCK1 (0.62) | ROCK1MAPK8MAPK9MKNK1MKNK2 | |
| SCHEMBL6071629 | 0.76 | ROCK1 (0.62) | ROCK1MAPK8MAPK9MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | InventisBio Co., Ltd. (CN) | 2021-12-21 | — | — | US | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| EP-3885344-A2 | PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2021-09-29 | — | — | EP | disclosed |
| CN-109328059-B | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190152969-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | INVENTISBIO SHANGHAI LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| CN-109328059-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2019-02-12 | — | — | CN | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2019-01-15 | — | — | US | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2012135697-A2 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| CN-1227249-C | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-11-16 | — | — | CN | disclosed |
| US-6716831-B1 | INHIBITION OF FOCAL ADHESION KINASE | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| EP-1161428-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| CN-1349528-A | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2002-05-15 | — | — | CN | disclosed |
| EP-1161428-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000053595-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152969-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | ROCK1 2582/4885MAPK8 119/4885MAPK9 225/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | ROCK1 2582/4885MAPK8 119/4885MAPK9 225/4885 |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | ROCK1 1/4885MAPK8 658/4885MAPK9 441/4885 |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | ROCK1 311/4885MAPK8 463/4885MAPK9 379/4885 |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, TP53 | ROCK1 3744/4885MAPK8 167/4885MAPK9 215/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | ROCK1 311/4885MAPK8 463/4885MAPK9 379/4885 |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, DPYD | ROCK1 2582/4885MAPK8 119/4885MAPK9 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.